The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, Arizona lawsuit says ...

Discover why oral phenylephrine in cold medicine is ineffective for relieving congestion. Learn which alternative treatments ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...